BCG vaccine-associated suppurative lymphadenitis

Vaccine

Volumn 23, Issue 20, 2005, Pages 2676-2679

  Teo, Stephen S S ^a   Smeulders, Naima ^b   Shingadia, Delane V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

BCG; Lymphadenitis; Vaccine

Indexed keywords

BCG VACCINE;

ABSCESS; ARTICLE; AXILLARY LYMPH NODE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEALTH CARE FACILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; LYMPHADENITIS; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 15044350326     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.07.052     Document Type: Article

References (17)

1. A. Lotte, O. Wasz-Hockert, N. Poisson, N. Dumitrescu, M. Verron, and E. Couvet BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics Adv Tuberc Res 21 1984 107 193
2. A. Lotte, O. Wasz-Hockert, and N. Poisson Second IUATLD study on complications induced by intradermal BCG-vaccination Bull Int Union Tuberc Lung Dis 63 2 1988 47 59
3. J.B. Milstien, and J.J. Gibson Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety Bull World Health Organ 68 1 1990 93 108
4. Troop, P. Important Information for Medical and Healthcare Professionals about new BCG Vaccine Statens Serum Institut (SSI). http://www.doh.gov.uk/bcg/ bcgletter.pdf (accessed 27 January 2004).
5. J. Harper Handbook of paediatric dermatology 1985 Butterworths London
6. M.A. Behr BCG - different strains, different vaccines? Lancet Infect Dis 2 2 2002 86 92
7. J. Guld, K. Magnus, K. Tolderlund, K. Biering-Sorensen, and P.Q. Edwards Suppurative lymphadenitis following BCG vaccination of the newborn: a preliminary report BMJ II 4947 1955 1048 1054
8. WHO Tuberculosis Research Office. Suppurative lymphadenitis following intradermal BCG vaccination of pre-school children. Bull World Health Organ 1955;12:143-67.
9. Statens Serum Institut. Summary of Product Characteristics: BCG Vaccine, MRP-SPC. http://www.serum.dk/sw2853.asp (accessed 31 March 2004).
10. Evans Vaccines. Summary of product characteristics. June 2002.
11. S.A. Banani, and A. Alborzi Needle aspiration for suppurative post-BCG adenitis Arch Dis Child 71 5 1994 446 447
12. P.K. Noah, D. Pande, B. Johnson, and D. Ashley Evaluation of oral erythromycin and local isoniazid instillation therapy in infants with Bacillus Calmette-Guerin lymphadenitis and abscesses Pediatr Infect Dis J 12 2 1993 136 139
13. N. Kuyucu, S. Kuyucu, B. Ocal, and T. Tezic Comparison of oral erythromycin, local administration of streptomycin and placebo therapy for nonsuppurative Bacillus Calmette-Guerin lymphadenitis Pediatr Infect Dis J 17 6 1998 524 525
14. J.S. Goraya, and V.S. Virdi Treatment of Calmette-Guerin bacillus adenitis: a metaanalysis Pediatr Infect Dis J 20 6 2001 632 634
15. North East London TB Network. Tuberculosis Notifications, 1987-2003. Rates per 100,000 population. Connections: The Newsletter of the North East London Tuberculosis Network (issue 6); March 2004.
16. Tuberculosis Section Communicable Disease Surveillance Centre London. Preliminary annual report on tuberculosis cases reported in 2002 in England, Wales and Northern Ireland; March 2004. http://www.hpa.org.uk/infections/ topics_az/tb/pdf/2002_Preliminary_Annual_Report.pdf (accessed 31 March 2004).
17. Department of Health. Tuberculosis: BCG immunisation. In: Immunisation against Infectious Disease. http://www.doh.gov.uk/greenbook/greenbookpdf/ chapter-32-layout.pdf (accessed 27 January 2004).